FGL common uses, half-life, side effects and more

FGL is a synthetic peptide derived from a piece of the brain-cell adhesion protein NCAM. It was designed to switch on a growth-factor receptor called FGFR1 that helps brain cells form and keep their connections. It was studied in animals for Alzheimer's disease, stroke, and memory. It reached one small human safety study before development stopped. It is not approved anywhere and is sold only as a research chemical. One finding stands out for anyone considering it. Animal studies found FGL protected injured or diseased brains. One study also found it damaged healthy ones. A healthy brain is the state most people taking it are in.

• Memory and learning enhancement
• Age-related cognitive decline and Alzheimer's-type support
• Recovery after stroke or brain injury
• Mood and stress resilience
• Neurogenesis and synaptic plasticity

Once daily, five days on and two off

Community use is subcutaneous at about 1 to 2 mg once daily on a five-days-on and two-days-off cycle. Under-30 users often start at 1 mg. This comes from a single practitioner protocol rather than a trial. The reports agree mainly because they share that one source. The human Phase 1 used far larger single doses of 25 to 200 mg. Those were one-time nasal-spray tolerability doses rather than a repeated injection dose. Rodent studies used 2 to 10 mg per kilogram under the skin. Some online guides list much higher figures such as 10 mg by injection. Those come from sites that invent numbers and cite papers that do not exist.

No half-life has been published for FGL in any species. Rat studies show it appearing in the blood and cerebrospinal fluid within minutes and clearing within a few hours. Its effect on brain-cell signaling lasts longer than that.

• Transient nasal irritation or watery eyes from intranasal use (seen in the single-dose human study)
• Injection-site reactions common to subcutaneous peptide use but not specifically studied for FGL
• Possible heightened anxiety since the clinical form was acutely anxiogenic in animals

FGL copies the part of NCAM that binds the FGFR1 receptor and activates it directly. That activation drives the MAPK and PI3K-AKT signaling pathways and the CREB pathway inside neurons. Downstream it promotes AMPA-receptor trafficking, long-term potentiation, new synapses, and neuronal survival. A separate anti-inflammatory action lowers IL-1beta and calms activated microglia in aged and injured brain tissue.

The evidence is preclinical and mixed. Animal studies from one research group and its collaborators reported benefits on memory, long-term potentiation, protection after stroke and brain injury, rescue of amyloid-related deficits, fewer seizures, and reduced brain inflammation. The same body of work carries an important warning. One study found it reduced neurons in a healthy brain instead of protecting it. Human evidence is a single small Phase 1 nasal-spray safety study in 24 men. A Phase 2 in Alzheimer's was announced but never registered or published. No human stroke trial was ever run. Development stopped after that Phase 1. The exact form also matters. Research chemicals are usually sold as the single-unit peptide while the studies used two-unit and four-unit versions. Potency does not carry across those forms.

• A small animal study found FGL cut healthy-brain neurons by about 40% while protecting diseased ones so its safety in a healthy person is a real concern
• FGL switches on the FGFR1 pathway that drives many cancers so it is unwise with any personal or family history of cancer
• No study has ever tested FGL for tumor growth so its cancer risk is a theoretical concern from the mechanism rather than a proven harm
• Human safety rests on one single-dose intranasal study in 24 men with no repeat-dose or long-term data
• Avoid FGL in pregnancy, breastfeeding, and anyone under 18
• Gray-market FGL is unregulated and often does not state which multi-unit form it is despite the forms differing sharply in potency